Albany Molecular Research Inc. (AMRI) has signed a collaborative agreement with the biotechnology company, HarkerBIO LLC to co-market its structure-based drug-discovery services to global pharmaceutical and biotechnology clients. As part of the three-year agreement, AMRI gains access to HarkerBIO’s differentiated high-resolution, structure-determination expertise and capabilities. HarkerBIO’s customers will be able to access and benefit from AMRI’s global capabilities, including their integrated drug-discovery platforms and solutions.

Aimed at accelerating decision making and success in the translation from discovery to the clinic, the alliance with HarkerBIO is an early example of the types of partnerships AMRI is creating. AMRI’s new discovery center is co-located on the Buffalo Niagara Medical Campus.

AMRI is a global contract research and manufacturing organization with locations in North America, Europe and Asia. Its key business segments include Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API) and Drug Product Manufacturing. Its DDS segment provides services from hit identification to investigational new drug applications, including expertise with diverse chemistry, library design and synthesis, in vitro biology and pharmacology, drug metabolism and pharmacokinetics, as well as natural products. API Manufacturing supports the chemical development and cGMP manufacture of complex APIs, including potent, controlled substances, biologics, peptides, steroids and cytotoxic compounds. Drug Product Manufacturing supports drug product development through commercial scale production of complex liquid-filled and lyophilized parenteral formulations.

The Buffalo Medical Innovation and Commercialization Hub at the Buffalo Niagara Medical Campus is part of a 10-year, $1 billion public-private research and development initiative announced by New York Governor Andrew M. Cuomo in December 2012.

Source: AMRI